RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Direct comparison of the effects of functionally equivalent dosing regimens of methamphetamine, methcathinone, and α-pyrrolidinopropiophenone on behavioral and neurochemical markers of stimulant-induced neurotoxicity
Chitre, N. M., Gannon, B. M., Blough, B. E., & Murnane, K. S. (2026). Direct comparison of the effects of functionally equivalent dosing regimens of methamphetamine, methcathinone, and α-pyrrolidinopropiophenone on behavioral and neurochemical markers of stimulant-induced neurotoxicity. Behavioural Pharmacology. Advance online publication. https://doi.org/10.1097/FBP.0000000000000899
Given that previous studies have provided mixed results on cathinone neurotoxicity, we compared the effects of 'functionally equivalent' dosing regimens of methamphetamine (METH), methcathinone, and α-pyrrolidinopropiophenone (α-PPP) on behavioral and neurochemical markers associated with dopaminergic alterations and cognitive function. Male Swiss Webster mice received METH (5 mg/kg), methcathinone (80 mg/kg), or α-PPP (80 mg/kg), using a 'binge'-like dosing regimen (q2h × 4, intraperitoneal). Body weight and temperature were recorded during dosing. Behavior was assessed 2-4 days later, followed by brain extraction. Motor function was evaluated by open-field testing and stride length analysis. Cognitive function was assessed with the passive avoidance test. Striatal levels of dopamine and its major metabolites were measured using ultra-HPLC. All three drug treatments induced weight loss. METH treatment produced a small, transient increase in rectal temperature (~1 °C); methcathinone and α-PPP did not. All three drug treatments impaired passive avoidance performance (P < 0.05 to P < 0.01), but none produced persistent motor deficits. METH and methcathinone treatment significantly reduced striatal dopamine levels (P < 0.001), whereas α-PPP did not, and only METH treatment increased homovanillic acid/dopamine turnover (P < 0.01). Only METH exposure triggered measurable changes in dopamine metabolism and a small, transient increase in temperature, highlighting its distinct neurochemical profile compared with methcathinone and α-PPP under these conditions. All three drug treatments impaired passive avoidance performance, but none caused lasting motor deficits, demonstrating that behavioral deficits can occur without persistent motor changes.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.